A 17-year-old cystic fibrosis warrior and liver transplant recipient with antibiotic resistance got to see science in action at Vanderbilt Medical Laboratories.

The project aims to design computational “tool kits” that can speed development of multi-virus vaccines targeting some of the greatest infectious threats to human health.

The study findings point to the potential of interleukin-13 antibodies — approved for use in humans — as a treatment to protect against bacterial pneumonia in patients with zinc deficiency.

While it has been difficult to pinpoint the reason for the rise in cases, waning immunity and vaccine hesitancy may be the likely culprits.

The study, a randomized and controlled clinical trial, tested the effectiveness of montelukast in 1,250 outpatients with acute post-COVID-19 symptoms.

Person, an award citation reads in part, “has been a champion for empathy and equity in caring for patients. ... She models for her learners how to compassionately care.”

Single-cell analysis reveals the inner workings of the life-threatening adverse drug reactions Stevens-Johnson syndrome and toxic epidermal necrolysis.